Get started
Author

Jiandong Yu

Observed names: Can Xu, Jian-Dong Yu
ORCID: 0009-0006-1785-2957
Observed ORCID: 0009-0006-1785-2957
OpenAlex ID: A5110696316
Re-detection and a possible time variation of soft X-ray polarization from the Crab
2020 · Hua Feng, Hong Li, et al. · Nature Astronomy · 81
PDF
GRID: a student project to monitor the transient gamma-ray sky in the multi-messenger astronomy era
2019 · Jiaxing Wen, Xiangyun Long, et al. · Experimental Astronomy · 73
PDF
A Significant Detection of X-ray Polarization in Sco X-1 with PolarLight and Constraints on the Corona Geometry
2022 · Xiangyun Long, Hua Feng, et al. · The Astrophysical Journal Letters · 56
Compact CubeSat Gamma-ray detector for GRID mission
2021 · Jia-Xing Wen, Xu-Tao Zheng, et al. · Nuclear Science and Techniques · 36
PDF
X-Ray Polarimetry of the Crab Nebula with PolarLight: Polarization Recovery after the Glitch and a Secular Position Angle Variation
2021 · Xiangyun Long, Hua Feng, et al. · The Astrophysical Journal Letters · 21
PDF
CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
2024 · Yang Xu, Xuzhao Zhang, et al. · Cancer Immunology Research · 12
In-orbit operation and performance of the CubeSat Soft X-ray polarimeter PolarLight
2020 · Hong Li, Xiangyun Long, et al. · Advances in Space Research · 11
PDF
Author Correction: Re-detection and a possible time variation of soft X-ray polarization from the Crab
2020 · Hua Feng, Hong Li, et al. · Nature Astronomy · 10
PDF
Discrimination of background events in the PolarLight X-ray polarimeter
2021 · Jiahuan Zhu, Hong Li, et al. · Research in Astronomy and Astrophysics · 9
PDF
Figure S2 from CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
2026 · Yang Xu, Xuzhao Zhang, et al.
Figure S4 from CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
2026 · Yang Xu, Xuzhao Zhang, et al.
Figure S3 from CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
2026 · Yang Xu, Xuzhao Zhang, et al.
Figure S1 from CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
2026 · Yang Xu, Xuzhao Zhang, et al.
Table S1 from CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
2025 · Yang Xu, Xuzhao Zhang, et al.
Figure S4 from CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
2025 · Yang Xu, Xuzhao Zhang, et al.
Figure S1 from CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
2025 · Yang Xu, Xuzhao Zhang, et al.
Figure S2 from CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
2025 · Yang Xu, Xuzhao Zhang, et al.
Figure S3 from CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
2025 · Yang Xu, Xuzhao Zhang, et al.
Data from CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
2025 · Yang Xu, Xuzhao Zhang, et al.
Works count: 20
Citation count: 382
H-index: 9
I10-index: 9
Year
Topic
Type